Changes in Beneficial Ownership · 4
ProKidney Corp.
PROKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-18
- Issuer
- PROKIDNEY CORP.
- Issuer CIK
- 0001850270
- Trading symbol
- PROK
Reporting owner 1
- Name
- Pereira Brian JG
- Reporting owner CIK
- 0001298146
- Relationship
- Director
- Address
- C/O PROKIDNEY CORP, 2000 FRONTIS PLAZA BLVD, SUITE 250, WINSTON SALEM, NC, 27103
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-08-18 | S · Form 4 | 229,338 | D | 1.3712[F1] | 445,897 | I | By Brian J. G. Pereira 2012 Irrevocable Trust |
| Class A Common Stock | 2026-08-18 | S · Form 4 | 27,826 | D | 1.3712[F1] | 54,103 | D | |
| Class A Common Stock | 2026-08-19 | S · Form 4 | 222,949 | D | 1.4407[F2] | 222,948 | I | By Brian J. G. Pereira 2012 Irrevocable Trust |
| Class A Common Stock | 2026-08-19 | S · Form 4 | 27,051 | D | 1.4407[F2] | 27,052 | D | |
| Class A Common Stock | 2026-08-20 | S · Form 4 | 222,948 | D | 1.4199[F3] | 0 | I | By Brian J. G. Pereira 2012 Irrevocable Trust |
| Class A Common Stock | 2026-08-20 | S · Form 4 | 27,052 | D | 1.4199[F3] | 0 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
- I
- Indirect
Footnotes
- F1
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1↩ 2
- F2
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1↩ 2
- F3
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1↩ 2
Signature 1
- Signed
- /s/ Todd Girolamo, attorney in fact
- Date
- 2026-08-20
Company context
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.